Literature DB >> 18718937

Protective role of Engrailed in a Drosophila model of Huntington's disease.

Bruno Mugat1, Marie-Laure Parmentier, Nathalie Bonneaud, Ho Yin Edwin Chan, Florence Maschat.   

Abstract

Huntington's disease (HD) is caused by the expansion of the polyglutamine (polyQ) tract in the human Huntingtin (hHtt) protein (polyQ-hHtt). Although this mutation behaves dominantly, htt loss of function may also contribute to HD pathogenesis. Using a Drosophila model of HD, we found that Engrailed (EN), a transcriptional activator of endogenous Drosophila htt (dhtt), is able to prevent aggregation of polyQ-hHtt. To interpret these findings, we tested and identified a protective role of N-terminal fragments of both Drosophila and Human wild-type Htt onto polyQ-hHtt-induced cellular defects. In addition, N-terminal parts of normal hHtt were also able to rescue eye degeneration due to the loss of Drosophila endogenous dhtt function. Thus, our data indicate that Drosophila and Human Htt share biological properties, and confirm a model whereby EN activates endogenous dhtt, which in turn prevents polyQ-hHtt-induced phenotypes. The protective role of wild-type hHtt N-terminal parts, specifically onto polyQ-hHtt-induced cellular toxicity suggests that the HD may be considered as a dominant negative disease rather than solely dominant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718937     DOI: 10.1093/hmg/ddn255

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  13 in total

1.  Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease.

Authors:  Juliette D Godin; Ghislaine Poizat; Miriam A Hickey; Florence Maschat; Sandrine Humbert
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

Review 2.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 3.  Recent advances in using Drosophila to model neurodegenerative diseases.

Authors:  Bingwei Lu
Journal:  Apoptosis       Date:  2009-08       Impact factor: 4.677

4.  Chemical interference with DSIF complex formation lowers synthesis of mutant huntingtin gene products and curtails mutant phenotypes.

Authors:  Ning Deng; Yun-Yun Wu; Yanan Feng; Wen-Chieh Hsieh; Jen-Shin Song; Yu-Shiuan Lin; Ya-Hsien Tseng; Wan-Jhu Liao; Yi-Fan Chu; Yu-Cheng Liu; En-Cheng Chang; Chia-Rung Liu; Sheh-Yi Sheu; Ming-Tsan Su; Hung-Chih Kuo; Stanley N Cohen; Tzu-Hao Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

5.  Hsp40 overexpression in pacemaker neurons delays circadian dysfunction in a Drosophila model of Huntington's disease.

Authors:  Pavitra Prakash; Arpit Kumar Pradhan; Vasu Sheeba
Journal:  Dis Model Mech       Date:  2022-06-28       Impact factor: 5.732

Review 6.  Biology in balance: human diploid genome integrity, gene dosage, and genomic medicine.

Authors:  James R Lupski
Journal:  Trends Genet       Date:  2022-04-18       Impact factor: 11.821

7.  Drosophila Models of Huntington's Disease exhibit sleep abnormalities.

Authors:  Erin Gonzales; Jerry Yin
Journal:  PLoS Curr       Date:  2010-09-29

8.  Cytotoxicity of mutant huntingtin fragment in yeast can be modulated by the expression level of wild type huntingtin fragment.

Authors:  Aliabbas Ahmedbhai Saleh; Ankan Kumar Bhadra; Ipsita Roy
Journal:  ACS Chem Neurosci       Date:  2014-01-08       Impact factor: 4.418

Review 9.  Drosophila models of proteinopathies: the little fly that could.

Authors:  Diego E Rincon-Limas; Kurt Jensen; Pedro Fernandez-Funez
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

10.  A huntingtin peptide inhibits polyQ-huntingtin associated defects.

Authors:  Yoan Arribat; Nathalie Bonneaud; Yasmina Talmat-Amar; Sophie Layalle; Marie-Laure Parmentier; Florence Maschat
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.